Another set of strong financials from Recordati

8 November 2023

Italian pharma major Recordati (RECI: MI) saw its shares rise 3.6% to 45.57 euros yesterday, after it released a strong set of financial results for the first-nine months of 2023.

The company revealed that nine-month consolidated revenue was 1,556.2 million euros ($1,66.4 million), +13.0% compared to the same period of 2022 or +13.8% on a like-for-like basis at constant exchange rates (CER), driven by the excellent performance of all business areas, with both Specialty and Primary Care and Rare Diseases continuing to post double-digit organic growth (at CER).

Adjusted net income was € 406.6 million, +14.2% over the same period in 2022, at 26.1% of revenue. Net income came in at 304.5 million euros, up 26.1% over the same period in 2022, at 19.6% of revenue, with the increase reflecting strong operating performance and the lower non-recurring expenses, absorbing in the third quarter a non-monetary adjustment to the unwind of the fair value of acquired oncology inventory due to the higher product sales, said Recordati.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK